

United States Patent and Trademark Office  
- Sales Receipt -

03/31/2006 TPLUNKET 00000001 501212 10675860  
Sale Ref: 00000001 DA#: 501212 10675860  
01 FC:2201 500.00 DA  
02 FC:2202 375.00 DA

## PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Title: NUCLEASE INHIBITOR COCKTAIL  
Appl. No.: 10/675,860  
Applicant: Kudlicki *et al.*  
Filed: September 30, 2003  
Art Unit: 1634  
Examiner: Whisenant, Ethan C.  
Docket No.: AMBI:052USC1

RECEIVED  
CENTRAL FAX CENTER  
MAR 29 2006

<b>CERTIFICATE OF FACSIMILE TRANSMISSION</b> 37 C.F.R. § 1.8 I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, facsimile number (571) 273- 8300 on the date below: March 29, 2006 Date Michael R. Krawczek
---

**RESPONSE TO THE NOTICE OF**  
**NON-COMPLIANT AMENDMENT MAILED MARCH 15, 2006**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit this response to the Notice of Non-Compliant Amendment mailed  
March 15, 2006, in the above case.

Amendments to the Claims are reflected in the listing of claims which begins on page 2.

Remarks begin on page 10.

FAST AVAILABLE COPY

50-1212

2201 @ 5 = 500  
2202 @ 15 = 375

25639900.1

1

and 69 (emphasis added). Again, Devaux *et al.* appear to concern “[m]ixtures of five inactivating Mabs” and not Applicants’ claimed combination of “a soluble anti-nuclease antibody” and “a non-antibody nuclease inhibitor.”

Because Devaux *et al* fails to disclose every element of Applicants’ claimed invention, the anticipation rejection cannot be maintained. *Telemac Cellular Corp. v. Topp Telecom, Inc.*, 247 F.3d at 1327. Applicants therefore request that the rejection of claims 51-54, 57-58, 59, 64, 68-69, 71-73, and 75-77 under 35 U.S.C. § 102(b) as being anticipated by Devaux *et al.* be withdrawn.

**C. The Double Patenting Rejections Are Overcome**

There are two separate obviousness-type double patenting rejections: (1) claims 51-79 as being unpatentable over claims 1-33 of U.S. Patent No. 6,664,379; and (2) claims 51-79 as being provisionally unpatentable over claims 1-82 of U.S. Patent Application No. 10/786,875. Applicants are filing the appropriate terminal disclaimers along with the present response. In view of this, the obviousness-type double patenting rejections are overcome and should be withdrawn.


**D. Conclusion**

Applicants believe that this document is a complete response to the Office Action mailed on December 5, 2005. The present claims are in a condition for allowance and such favorable action is requested.

The Commissioner is hereby authorized to deduct any fees required by 37 C.F.R. §§ 1.116 to 1.21 as a result of the filing of this paper, including the terminal disclaimer fees required by 37 C.F.R. § 1.20(d), from Fulbright & Jaworski Deposit Account No. 50-1212/AMBI:052USC1.

The Examiner is requested to contact Applicant's representative at (512) 536-3035 with any questions or comments concerning this application.

Respectfully submitted,



Michael R. Krawzsenek  
Reg. No. 51,898  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.536.3020 (voice)  
512.536.4598 (fax)

Date: March 1, 2006